To evaluate signal enhancement ratio (SER) for tissue characterization and prognosis stratification in pancreatic adenocarcinoma (PDAC), with quantitative histopathological analysis (QHA) as the reference standard.
Methods
This retrospective study included 277 PDAC patients who underwent multi-phase contrast-enhanced (CE) MRI and whole-slide imaging (WSI) from three centers (2015–2021). SER is defined as (SIlt − SIpre)/(SIea − SIpre), where SIpre, SIea, and SIlt represent the signal intensity of the tumor in pre-contrast, early-, and late post-contrast images, respectively. Deep-learning algorithms were implemented to quantify the stroma, epithelium, and lumen of PDAC on WSIs. Correlation, regression, and Bland-Altman analyses were utilized to investigate the associations between SER and QHA. The prognostic significance of SER on overall survival (OS) was evaluated using Cox regression analysis and Kaplan–Meier curves.
Results
The internal dataset comprised 159 patients, which was further divided into training, validation, and internal test datasets (n = 60, 41, and 58, respectively). Sixty-five and 53 patients were included in two external test datasets. Excluding lumen, SER demonstrated significant correlations with stroma (r = 0.29–0.74, all p < 0.001) and epithelium (r = −0.23 to −0.71, all p < 0.001) across a wide post-injection time window (range, 25–300 s). Bland-Altman analysis revealed a small bias between SER and QHA for quantifying stroma/epithelium in individual training, validation (all within ± 2%), and three test datasets (all within ± 4%). Moreover, SER-predicted low stromal proportion was independently associated with worse OS (HR = 1.84 (1.17–2.91), p = 0.009) in training and validation datasets, which remained significant across three combined test datasets (HR = 1.73 (1.25–2.41), p = 0.001).
Conclusion
SER of multi-phase CE-MRI allows for tissue characterization and prognosis stratification in PDAC.
Clinical relevance statement
The signal enhancement ratio of multi-phase CE-MRI can serve as a novel imaging biomarker for characterizing tissue composition and holds the potential for improving patient stratification and therapy in PDAC.
Key Points
Imaging biomarkers are needed to better characterize tumor tissue in pancreatic adenocarcinoma.
Signal enhancement ratio (SER)-predicted stromal/epithelial proportion showed good agreement with histopathology measurements across three distinct centers.
Signal enhancement ratio (SER)-predicted stromal proportion was demonstrated to be an independent prognostic factor for OS in PDAC.
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AP
Arterial phases
DCE-MRI
Dynamic contrast-enhanced magnetic resonance imaging
DP
Delayed phases
PDAC
Pancreatic adenocarcinoma
PVP
Portal venous phases
QHA
Quantitative histopathological analysis
ROI
Region of interest
SER
Signal enhancement ratio
WSI
Whole-slide image
Introduction
Pancreatic adenocarcinoma (PDAC) is one of the most lethal cancers with a dismal 5-year survival rate of 11% [1]. A hallmark feature of PDAC is its extensive desmoplastic stroma, which is thought to confer biological aggressiveness [2, 3]. It is reported that this dense stroma acts as a physical barrier to hinder the effective delivery of drugs [4, 5]. Moreover, the amount of stroma displays remarkable variability within the tumors as well as among patients, and this variability has been shown to yield prognostic information [6]. Generally, a low proportion of stroma predicts an unfavorable prognosis in PDAC [7‐10]. However, current clinical imaging assessments predominantly rely on shape-based and volume-based descriptors [11]. There is a strong need to identify imaging biomarkers for characterizing tumor tissue composition in PDAC.
Multi-phase dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a highly sensitive modality for tumor characterization when compared to CT, owing to its superior soft tissue contrast and ability to provide functional information [12]. Quantitative parameters such as the volume transfer constant, Ktrans, have yielded some preliminary results in stroma estimation [13]. However, the technical complexities and relatively low image quality due to lower spatial resolution compared to conventional multi-phase contrast-enhanced MRI (CE-MRI), are major obstacles preventing the widespread use of quantitative parameters [14]. In contrast, signal enhancement ratio (SER) is a semiquantitative method to estimate signal intensity changes through a three-time-point examination [15]. Specifically, SER is defined as (SIlt − SIpre)/(SIea − SIpre), where SIpre, SIea, and SIlt represent the signal intensity (SI) on pre-contrast, early post-contrast, and late post-contrast images, respectively. Previous studies have demonstrated close associations between SER and tumor biological behavior as well as prognostic outcomes in breast cancer [15, 16]. Nevertheless, few studies have investigated the potential of SER for PDAC tissue characterization.
Anzeige
With advances in digital pathology, Hao Fu et al proposed the first deep-convolutional neural network architecture for PDAC detection [17]. Bo Li et al employed a conditional generative adversarial model to segment tumors and stroma on whole-slide images (WSIs) [9]. These advancements facilitate an objective and standardized assessment of tumor tissue composition. However, to the best of our knowledge, the relationship between SER and quantitative tumor tissue composition has not been investigated in PDAC. Therefore, the objective of our study was to evaluate the potential of SER derived from multi-phase CE-MRI for characterizing tissue composition in PDAC, with quantitative histopathological analysis (QHA) as the reference standard. The prognostic value of SER was also analyzed.
Methods
Study patients
This retrospective study was approved by the institutional review board and the requirement for written informed consent was waived.
The study comprised consecutive patients with PDAC who underwent upfront surgery and preoperative multi-phase CE-MRI from three academic centers in China between 2015 and 2021. The internal dataset included patients who underwent either a 16-phase DCE-MRI or conventional multi-phase CE-MRI from Henan Cancer Hospital, Zhengzhou (Center A). Among patients with 16-phase DCE-MRI, a division was made into a training dataset (encompassing scans obtained 2015–2019) and a validation dataset (encompassing scans obtained 2020–2021). Patients who underwent conventional CE-MRI constituted an independent internal test dataset. Two external test datasets were included, consisting of patients who underwent conventional multi-phase CE-MRI at Xiangya Hospital of Central South University, Changsha (Center B), and Subei People’s Hospital, Yangzhou (Center C), respectively.
The inclusion criteria for all patients were as follows: (i) upfront surgical resection with histopathological confirmation of PDAC, (ii) preoperative multi-phase CE-MRI within one month of surgery, and (iii) the availability of hematoxylin and eosin (H&E)-stained WSIs from tumor resections. The exclusion criteria were as follows: (i) inadequate MRI quality, (ii) missing or less than three WSIs, and (iii) absence of clinical data. The participant flowchart is shown in Fig. 1.
Fig. 1
Flowchart of the patient selection process in training, validation, internal test, and two external test datasets. PDAC, pancreatic adenocarcinoma; DCE-MRI, dynamic contrast-enhanced MRI; WSIs, whole-slide images
×
Anzeige
MRI protocol and analysis
MRI protocol
The acquisition parameters for MRI are detailed in Appendix E1 and Table E1 and E2. In training and validation datasets, the MR sequences included 16-phase DCE-MRI, diffusion-weighted imaging (DWI), and T2-weighted imaging (T2WI). The acquisition of 16-phase DCE-MRI employed the CAIPIRINHA-Dixon-TWIST-VIBE technique. This technique involved capturing one pre-contrast phase (PRE), six consecutive arterial phases (AP) from 15 to 37 s after contrast injection, six consecutive portal venous phases (PVP) from 50 to 72 s, and followed by three delayed phases (DP) at 90, 150, and 300 s. For DWI, a single-shot echo-planar imaging pulse sequence was utilized with b-values of 50 and 800 s/mm2. Subsequently, apparent diffusion coefficient (ADC) maps were generated from the DWI scans of both b-values. In the internal and two external test datasets, conventional multi-phase CE-MRI was acquired with one PRE, AP (15–25 s), PVP (50–55 s), and DP (120–180 s).
Imaging preprocess and region of interest (ROI) measurements
For batch extraction of the region of interest (ROI) measurements, a grid and deformable registration technique via Elastix (https://elastix.lumc.nl/) was employed to achieve voxel-wise alignment for multi-phase CE-MRI images. Subsequently, ROIs for the tumor and paraspinal muscle were drawn by two radiologists (C.X. and Z.B., with 7 and 4 years of abdominal imaging experience, respectively), see Appendix E1 (electronic supplemental material) for more details of ROI delineations. The SER of the tumor at multi-phase CE-MRI was calculated as follows [18]:
where \(\,{{SI}}_{{pre}}\),\(\,{{SI}}_{{ea}}\), and \({{SI}}_{{lt}}\) represent the signal intensity (SI) of the tumor ROI on pre-contrast, early post-contrast (AP or PVP: ranged from 15 to 72 s after contrast injection), and late post-contrast images (PVP or DP: ranged from 50 to 300 s), respectively. To assess the reproducibility of SER, two radiologists independently delineated the tumor ROIs on 16-phase DCE-MRI. Furthermore, in training and validation datasets, several additional parameters were acquired, including ADC values of the tumor, the tumor-to-muscle SI ratio on T2WI, and all pre- and post-contrast scans of 16-phase DCE-MRI.
SER analysis for quantifying tumor tissue composition
Given the wide post-injection time window of 16-phase DCE-MRI, we investigated the proper scanning timing of SER for characterizing tissue composition. Consistent with previous findings [13, 19], PDAC showed a rapid increase in enhancement during AP, followed by a gradual and slow increase in PVP and DP (Fig. S1). Consequently, for early post-contrast time point (Tea), we selected two clinically significant AP time points: The pancreatic parenchyma phase (approximately 35 s after contrast injection) is widely accepted as the optimal phase for detecting PDAC, while the late AP phase (approximately 25 s) is readily accessible and considered optimal for identifying liver tumors. Additionally, a commonly utilized PVP time point (approximately 50 s). Furthermore, for late post-contrast time points (Tlt), we analyzed all time points in PVP and DP, ranging from 50 (excluding Tea = 50) to 300 s, to investigate the impact of scan delay on tissue characterization. Spearman correlation analysis was employed to evaluate the correlation between SER and QHA. A time-r-value curve fitting analysis was combined to determine the optimal time points of Tea and Tlt for characterizing tissue composition.
To assess the predictive capacity of SER for tissue quantification, the initial linear regression model was developed, using the SER at the optimally chosen Tea and Tlt time points in training datasets. This model was subsequently validated in an entirely separate validation dataset. In instances where the optimally chosen time points were not acquired on conventional CE-MRI, a second linear regression model, utilizing the SER that demonstrated the highest correlation with QHA based on conventional CE-MRI scanning timings, was further constructed in the training dataset. This second model was then tested in three different test datasets to evaluate its clinical generalizability on conventional CE-MRI. The SER-fitted tissue composition maps were generated by employing the corresponding regression model and performing voxel-based calculations using Python scripts.
Quantitative histopathological analysis (QHA)
Three or more H&E-stained slides from tumor resection were selected for each patient and digitized at × 40 magnification at respective institutions. Two deep-learning-based segmentation models were developed to quantify tumor tissue composition on WSIs: one is for tumor detection and the other is for tissue segmentation. Image annotation of the “normal” and “tumor” region, as well as the “stroma”, “epithelium”, and “lumen” tissue was performed using ASAP (https://computationalpathologygroup.github.io/ASAP/), by two pathologists (Y.C.G. and M.Y.S. with 6 years of experience in gastrointestinal pathology).
Tumor detection
A VGG-19-based convolutional neural network was trained to recognize the normal and tumor regions. A total of 453 WSIs were annotated by pathologists to establish the ground truth for model training and validation. Of these, 209 WSIs were obtained from a publicly accessible cohort of The Cancer Genome Altas-Pancreatic Adenocarcinoma (TCGA-PAAD), available at https://www.cancer.gov. Then, 244 WSIs were selected in a randomized, center-balanced manner from the pool of WSIs at Centers A, B, and C. A total of 16,061 patches of size 512 × 512 pixels were extracted for model training and validation at a ratio of 7:3.
Tissue segmentation
A U-Net-based neural network was employed to segment stroma, epithelium, and lumen, as in our previous work [20]. A total of 391 WSIs from five TCGA cohorts, namely PAAD, breast cancer, lung adenocarcinoma, lung squamous cell carcinoma, and stomach adenocarcinoma, were manually annotated for model training. Ninety WSIs were selected in a randomized, center-balanced manner from Centers A, B, and C, and annotated for model-independent validation. A total of 17,159 patches of size 512 × 512 pixels were generated for model training and validation at a ratio of 7:3.
Finally, the proportion of stroma, epithelium, and lumen was calculated as the percentages of specific tissue area within the tumor area across all WSIs. The segmentation results were checked by two pathologists, and corrections were made as necessary.
Statistical analysis
Statistical analyses were performed using SPSS (version 25.0, IBM; Armonk, NY, USA). Continuous and categorical variables were compared using the Kruskal–Wallis test and the Chi-square test or Fisher exact test, respectively. Interobserver agreements for SER were assessed using intraclass correlation coefficients (ICC). The agreements between SER and QHA for tissue quantification were evaluated through Bland-Altman plots and Pearson correlation tests. Survival analysis was performed on overall survival (OS), employing Kaplan–Meier curves with log-rank tests, and univariate- and multivariate Cox regression analyses. The cutoff point of stroma, epithelium, and SER for survival analysis was determined by their respective mean value. The significance level was set at p < 0.05, with a two-tailed approach for all analyses.
Results
Patient characteristics
A total of 277 patients were included in this study. The internal dataset comprised 159 patients from Center A, which was further divided into training, validation, and internal test datasets (n = 61, 40, 58, respectively). There were two external datasets from center B (n = 65) and center C (n = 53). The demographic and clinicalpathologic characteristics of the patients were largely balanced among the datasets (Table 1). Overall, 156 (56.3%) patients were male with a median age of 62 years (IQR, 54–68). The median intervals between MRI examinations and surgery were 3 (IQR, 2–6), 5 (4–7), 3 (2–6), 6 (3–8), and 6 (4–9) days for training, validation, internal test, and two external datasets, respectively.
Table 1
Clinicopathologic characteristics in training, validation, internal test, and two external datasets
Characteristics
Internal dataset (n = 159)
External datasets (n = 118)
p-value
Training (n = 61)
Validation (n = 40)
Internal test (n = 58)
External test 1 (n = 65)
External test 2 (n = 53)
Age (years)a
63 (56–68)
63 (56–70)
62 (53–66)
61 (52–67)
64 (54–71)
0.568
Sex (male)
34 (55.7)
21 (52.5)
32 (55.2)
37 (56.9)
32 (60.4)
0.958
CA 19-9 (> 37 U/mL)
47 (77.0)
28 (70.0)
44 (75.9)
47 (72.3)
37 (69.8)
0.875
Tumor location (head)
41 (67.2)
29 (72.5)
47 (81.0)
46 (70.8)
33 (62.3)
0.248
Tumor size (cm)a
3.5 (2.7–5.0)
3.5 (2.6–4.3)
3.5 (2.5–4.6)
3.0 (2.5–4.5)
2.8 (1.8–3.5)
0.004*
Pathological T stage
0.003*
T1
10 (16.4)
3 (7.5)
10 (17.2)
11 (16.9)
19 (35.9)
T2
31 (50.8)
26 (65)
26 (44.8)
35 (53.9)
30 (56.6)
T3
20 (32.8)
11 (27.5)
22 (37.9)
19 (29.2)
4 (7.5)
Pathological N stage
0.256
N0
76 (75.2)
31 (77.5)
43 (74.1)
46 (70.8)
31 (58.5)
N1 or N2
25 (24.8)
9 (22.5)
15 (25.9)
19 (29.2)
22 (41.5)
Pathological TNM stage (AJCC 8th edition)
0.787
I
31 (50.8)
18 (45)
31 (53.4)
34 (52.3)
28 (52.8)
II
27 (44.3)
20 (50)
27 (46.6)
28 (43.1)
22 (41.5)
III
3 (4.9)
2 (5)
0 (0)
3 (4.6)
3 (5.7)
Resection margin (R0)
58 (95.1)
39 (97.5)
46 (86.7)
62 (95.3)
48 (90.5)
0.650
Histological grade
0.880
Well or Moderate
48 (78.7)
33 (80.5)
48 (82.7)
51 (78.5)
45 (84.9)
Poor
13 (21.3)
7 (17.5)
10 (17.2)
14 (21.5)
8 (15.1)
CA carbohydrate antigen. * Indicates statistical significance; p < 0.05
aContinuous variables are presented with median and interquartile range and compared using the Kruskal–Wallis test; categorical variables are presented with numbers and percentages and compared using the Chi-square test or Fisher’s exact test
Quantitative histopathological analysis
QHA was performed on 1027 WSIs from 277 (3.7 ± 0.8) patients in all datasets. The tumor detection model achieved a mean area under the receiver operating characteristic curve (AUC) of 0.94. The tissue segmentation model achieved mean Dice similarity coefficients for stroma, epithelium, and lumen were 0.89, 0.90, and 0.79, respectively (see Fig. S2 for visual examples).
The average proportion of stroma, epithelium, and lumen was 59.7 ± 13.7%, 25.5 ± 11.2%, and 5.4 ± 3.0% in PDAC. Poorly differentiated tumors exhibited a higher proportion of epithelium (poor, 36.2 ± 11.5% vs. well/moderate, 23.0 ± 9.6%; p < 0.001), and a lower proportion of stroma (poor, 48.8 ± 13.9% vs. well/moderate, 62.2 ± 12.4%; p < 0.001) than well or moderately differentiated PDACs, excluding lumen. Given the low proportion of lumen, our subsequent analysis focused on stroma and epithelium.
Correlation analysis between QHA and MRI
For conventional MRI parameters, the tumor-to-muscle SI ratio on T2WI and all scans of 16-phase DCE-MRI showed negligible to significantly weak correlations with stroma (r, range −0.02 to 0.23) and epithelium (r, range −0.05 to −0.16); ADC showed weak yet significant correlations with stroma and epithelium (r = 0.32 and −0.29, respectively, both p < 0.001) in combined training and validation datasets.
In contrast, Fig. 2 illustrates the significant correlations that exist between SER and both stroma (r, range 0.29–0.74, all p < 0.001) and epithelium (r, range −0.23 to −0.71, all p < 0.001) across a wide post-injection time window (range from 25 to 300 s). The highest correlations with both stroma and epithelium (r = 0.74 and −0.71, respectively) are demonstrated by SER300_35, thereby establishing the optimal SER. Further analysis from the time-r-value curve fitting suggests a proper Tlt time window of approximately 150–300 s (all |r| > 0.5). In accordance, the highest correlations are exhibited when Tea = 35 (all |r| > 0.70), followed by Tea = 50 (all |r| > 0.55) and Tea = 25 s (all |r| > 0.50) (Fig. S3). For conventional CE-MRI scanning timing, the SER150_50 demonstrated the highest correlations with both stroma and epithelium (r = 0.63 and −0.58, respectively). The interobserver agreement for SER is good, with all ICC values exceeding 0.80 (range, 0.81–0.90).
Fig. 2
The SER and QHA correlation matrix in training and validation datasets. The Spearman correlation coefficients between SER and QHA measured the proportion of stroma (Stro%) and epithelium (Epi%) across various Tea and Tlt time points (columns (Tea) represent the three early-contrast time points and rows (Tlt) represent the late-contrast time points). SER, signal enhancement ratio; QHA, quantitative histopathological analysis. ** indicates p < 0.001
×
Linear regression analysis for tissue quantification
To evaluate the predictive capacity of SER for tissue quantification, linear regression analyses were performed and the model development results are summarized in Appendix E2 and Table E3. In Bland-Altman analysis, bias and 95% limits of agreement (LA) indicated good accuracy for stroma/epithelium quantification by using the optimal SER300_35 model in both training and validation datasets (all mean bias within ±1% and 95% LA within ± 20%). Moreover, the low standard error (all < 10%) suggested a high level of precision (refer to Table E4 for details). Pearson correlation test showed strong correlations between SER300_35 and QHA in training and validation datasets for quantifying stroma (r = 0.79 vs. 0.71, both p < 0.001) and epithelium (r = 0.76 vs. 0.63, both p < 0.001) (Fig. 3). The visual examples of the SER-fitted stroma/epithelium maps are shown in Fig. 4.
Fig. 3
Bland-Altman plot and Pearson correlation plot for stroma and epithelium. a–d showing the agreement of stroma and epithelium quantified by using SER300_35 and QHA in training and validation datasets, respectively. e–h showing the agreement of stroma and epithelium quantified by using SER150_50 and QHA in the internal and two external test datasets. Bland-Altman plot is presented with a mean bias (bold line) and 95% limits of agreement (dot line). SER, signal enhancement ratio; QHA, quantitative histopathological analysis. ** indicates p < 0.001
Fig. 4
The SER-fitted maps for characterizing stroma and epithelium in PDAC. a–c Showing three representative tumors consisting of a low (high) (a), medium (medium) (b), and high (low) proportion of stroma (epithelium) (c), respectively. The SER-fitted stroma and epithelium maps provide a directly visualizable assessment of the proportion of stroma and epithelium in PDAC. SER, signal enhancement ratio; WSIs, whole-slide images; QHA, quantitative histopathological analysis; Stro, stroma; Epi, epithelium
×
×
To validate the clinical generalizability of SER on conventional CE-MRI, the second regression model, utilizing SER150_50, was constructed and tested in the internal- and two external test datasets. Bland-Altman plots also showed a small bias between the measurements of SER150_50 and QHA in all three test datasets, with a mean bias of approximately ± 4% and 95% LA within ± 25% (see Table E4 for details). Pearson correlation test showed moderate correlations in three test datasets, for stroma (r = 0.60 vs. 0.52 vs. 0.60, all p < 0.001) and epithelium (r = 0.52 vs. 0.49 vs. 0.52, all p < 0.001) (Fig. 3).
Anzeige
Univariable and multivariable analyses for prognostic significance
Univariate and multivariate Cox regression analyses were performed in combined training and validation datasets. The binary categorical marker of stromal proportion predicted by SER300_35 was an independent predictor of OS (cutoff = 60%, for low vs. high, HR = 1.84, 95% CI: 1.17–2.91, p = 0.009) after adjustment for the histologic grade, pathological T and N stage, and resection margin (Table 2). Similar results were obtained for the continuous marker of stromal proportion predicted by SER300_35 (HR = 0.98 (0.96–1.00), p = 0.019) (Table E5).
Table 2
Univariable and multivariable Cox regression analysis of the OS in combined training and validation datasets
Parameters
Univariate
Multivariate
Hazard ratio
p-value
Hazard ratio
p-value
Age (> 65 vs. ≤ 65 years)
0.90 (0.58–1.39)
0.626
Sex (male vs. female)
0.86 (0.56–1.33)
0.497
CA19-9 level (> 37 vs. ≤ 37 U/mL)
1.15 (0.70–1.89)
0.574
Tumor location (head vs. body/tail)
1.05 (0.66-1.69)
0.834
Pathological T stage (T3 vs. T1-2)
1.38 (0.87–2.18)
0.17
1.10 (0.67–1.79)
0.712
Pathological N stage (N1-2 vs. N0)
1.79 (1.10–2.91)
0.019*
1.79 (1.10–2.93)
0.02*
Histological grade (poor vs. well/moderate)
3.07 (1.80–5.24)
< 0.001**
3.06 (1.73–5.41)
< 0.001**
Resection margin (R1 vs. R0)
3.14 (1.12–8.27)
0.03*
1.69 (0.55–5.13)
0.358
LVI (positive vs. negative)
1.27 (0.75–2.15)
0.379
Perineural invasion (positive vs. negative)
0.99 (0.62–1.57)
0.963
SER300_35 (low vs. high)
1.98 (1.28–3.07)
0.002*
...
...
Stro% predicted by SER300_35 (low vs. high)
1.96 (1.27–3.04)
0.003*
1.84 (1.17–2.91)
0.009*
Epi% predicted by SER300_35 (low vs. high)
0.64 (0.42–0.99)
0.049*
...
...
Adjuvant chemotherapy (yes vs. no)
0.75 (0.48–1.17)
0.211
Variables with p < 0.10 in the univariate analysis were included in the multivariate analysis. Data in parentheses are 95% confidence intervals
OS overall survival, LVI lymphovascular invasion, SER signal enhancement ratio, Stro% the proportion of stroma, Epi% the proportion of epithelium
* indicates p < 0.05, ** indicates p < 0.001
Kaplan–Meier curves demonstrated that the stromal proportion predicted by SER300_35 identified substantially different OS periods between two patient subgroups (median OS: low 10.1 vs. high 20.3 months, HR = 2.08 (1.30–3.32), p = 0.002). Notably, these findings were comparable to those obtained through QHA (low 10.7 vs. high 22.8 months, HR = 2.06 (1.30–3.26), p = 0.002). Similar findings were observed in the stromal proportion predicted by SER150_50 across three combined test datasets (low 15.3 vs. high 20.6 months, HR = 1.73 (1.25–2.41), p = 0.001), compared to QHA (low 15.0 vs. high 21.9 months, HR = 1.72 (1.23–2.41), p = 0.002) (Fig. 5).
Fig. 5
The prognostic value of stroma quantified by QHA and SER. Kaplan–Meier curves for overall survival (OS) according to the stromal proportion quantified by QHA (a), and SER300_35 (b) across the training and validation datasets, as well as QHA (c), and SER150_50 (d) across the internal and two external test datasets. Kaplan–Meier curves show that a low stromal proportion is significantly associated with worse OS in PDAC. QHA, quantitative histopathological analysis; SER, signal enhancement ratio; Stro, stroma
×
Discussion
Characterization of tumor tissue composition has shown promise for enhancing patient stratification and therapy in PDAC [3, 4, 21]. In this study, significant correlations were observed between SER and QHA-measured stroma/epithelium in PDAC. The high interobserver reproducibility of SER, coupled with its demonstrated concordance in tissue quantification with QHA across three distinct centers, reinforces its reliability and generalizability as a potential imaging biomarker for characterizing tissue composition in PDAC. Moreover, our analysis demonstrated that SER-predicted a low stromal proportion was independently associated with worse OS in training and validation datasets, and this association retained its significant prognostic value across three combined test datasets. These findings underscore the potential of SER for tissue characterization and prognostic stratification in PDAC.
The visual assessment of quantitative histopathological features is prone to interobserver variability, and thus we have developed deep-learning algorithms for QHA. Compared to previous studies [9, 17], our segmentation models have exhibited comparable performance in a relatively large multicenter dataset. Moreover, the stromal proportion measured by QHA is in line with prior studies by using immunohistochemical staining [22, 23], indicating the good accuracy of our segmentation models.
Anzeige
To investigate the optimal time points of SER for tissue characterization, our study utilized a 16-phase DCE-MRI, which offers a wider post-injection time window compared to conventional CE-MRI for PDAC characterization. Our investigation revealed that the optimal tissue characterization using SER may be achieved by combining Tea = 35 and Tlt = 300 s. These findings align with prior studies that have demonstrated a slow and gradual enhancement pattern in PDAC, with PPP providing the maximum contrast for PDAC detection [13, 19].
SER of multi-phase CE-MRI can provide a semiquantitative approximation of the redistribution rate constant [15, 18]. The correlation between SER and QHA may potentially be elucidated by different tissue contrast agent concentrations. Specifically, the stroma, which is comprised of dense fibrotic tissue, increases the volume of distribution for the contrast agent. Conversely, gadolinium is incapable of permeating intact cell membranes within the epithelium [14].
To the best of our knowledge, this is the first study to investigate SER as a potential imaging biomarker for quantifying tissue composition in PDAC. To assess the predictive capacity of SER, we developed a first linear regression model utilizing the optimal SER300_35. Our results demonstrated that the stromal/epithelial proportion predicted by SER300_35 exhibited a high level of agreement with the measurements of QHA, thereby supporting the efficacy of SER for tissue quantification. Furthermore, recognizing that SER may be influenced by varying scanning systems [18], we conducted additional validation using conventional CE-MRI data from three distinct centers. Despite the optimal time points not routinely captured in conventional CE-MRI [24‐26], the stromal/epithelial proportion predicted by SER150_50 still demonstrated a good agreement with the measurements of QHA. This finding further emphasizes the applicability and generalizability of SER for tissue quantification in clinical practice.
A majority of studies have shown that PDAC with a low proportion of stroma tends to exhibit worse histological grades and poorer outcomes [8‐10, 27, 28], which aligns with our findings. However, there exists conflicting evidence in the literature, suggesting that a low proportion of stroma predicts longer survival [23, 29]. This contradiction can partly be attributed to the limitations of small sample sizes and discrepancies in stroma quantification methods. Notably, the conflicting studies predominantly rely on subjective and random regional assessments or solely evaluate stroma in the most severe areas, both of which fail to adequately represent the entire tumor due to the spatial heterogeneity of PDAC [30]. In contrast, QHA enables an objective and standardized approach to analyze WSIs in multicenter cohorts. Our findings demonstrated that the stromal proportion predicted by SER achieved comparable performance to QHA in stratifying patients. Furthermore, when subjected to multivariate analysis, the SER-predicted stromal proportion remained an independent predictor in training and validation datasets, and demonstrated significant prognostic value across three test datasets. These findings might have significant implications for PDAC management.
Anzeige
Limitations
We acknowledge several limitations in our study. First, the retrospective design introduces potential bias in patient selection. Second, the sample size was relatively small after separating training, validation, and internal and external test datasets. Third, the retrospective nature of the study prevented us from conducting spatial registration between WSIs and MRI data. Furthermore, future studies should be conducted with prospective cohorts, preferably in a multicenter setting.
Conclusions
In conclusion, our study demonstrated that SER of multi-phase CE-MRI is a potential imaging biomarker for tissue composition characterization and prognosis stratification in PDAC.
We express our gratitude to TCGA for providing publicly available digital pathology data.
Funding
This research was supported by the National Key R&D Program of China (2021YFF0501504, and 2021YFA1101304); the National Natural Science Foundation of China (NSFC, No.82330060, 92059202, and 61821002); the National Tutor System Training Program for Health Youth Key Talents in Suzhou (Qngg2021006).
Compliance with ethical standards
Guarantor
The scientific guarantor of this publication is Sheng-hong Ju.
Conflict of interest
YS is an employee of Siemens Healthineers. The remaining authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
Bingwei Chen kindly provided statistical advice for this manuscript.
Informed consent
Written informed consent was waived by the Institutional Review Board.
Ethical approval
Institutional Review Board approval was obtained.
Study subjects or cohorts overlap
None.
Methodology
Retrospective
Diagnostic or prognostic study
Multicenter study
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Radiologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Radiologie, den Premium-Inhalten der radiologischen Fachzeitschriften, inklusive einer gedruckten Radiologie-Zeitschrift Ihrer Wahl.
Signal enhancement ratio of multi-phase contrast-enhanced MRI: an imaging biomarker for survival in pancreatic adenocarcinoma
verfasst von
Cong Xia Jin-rong Qu Yi-ping Jiao Chun-qiang Lu Ben Zhao Rong-jun Ge Yue Qiu Bu-yue Cao Qian Yu Tian-yi Xia Xiang-pan Meng Yang Song Li-hua Zhang Xue-ying Long Jing Ye Zhi-min Ding Wu Cai Sheng-hong Ju
Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.
Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.
Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.
In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.
Update Radiologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
